Michael B. Atkins, Md

This Phase 2 trial is testing a new combination of two immunotherapy drugs, botensilimab and balstilimab, against the standard combination of ipilimumab and nivolumab for people with advanced kidney cancer that has spread. The study plans to enroll 120 patients who have not had p…